.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR10_LopinavirAndRitonavir.LopinavirAndRitonavir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR10_LopinavirAndRitonavir.LopinavirAndRitonavir| name: | LopinavirAndRitonavir |
| ATC code: | J05AR10 | route: | oral |
| n-compartments | 2 |
Lopinavir and ritonavir is a fixed-dose combination of antiretroviral drugs used in the treatment and prevention of HIV/AIDS. Lopinavir inhibits the HIV-1 protease, while ritonavir acts mainly as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A-mediated metabolism of lopinavir, thereby increasing lopinavir plasma concentrations. This combination is approved and is a common part of highly active antiretroviral therapy (HAART) regimens used today.
Pharmacokinetic parameters reported in healthy adult subjects (both sexes) after oral administration of lopinavir/ritonavir 400 mg/100 mg twice daily in tablet formulation.
Zhang, C, et al., & Denti, P (2012). Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children. Antiviral therapy 17(1) 25–33. DOI:10.3851/IMP1915 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22267466
Moltó, J, et al., & Valle, M (2008). Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clinical pharmacokinetics 47(10) 681–692. DOI:10.2165/00003088-200847100-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18783298
Thakur, A, et al., & Chan, JCY (2020). Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2. Clinical pharmacology and therapeutics 108(6) 1176–1184. DOI:10.1002/cpt.2014 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32767755